brusatol has been researched along with Acute Myelogenous Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, S; Chen, XP; Cheng, C; Jiang, ZP; Yuan, F; Zhang, W; Zhao, XL; Zhou, G; Zhou, HH | 1 |
1 other study(ies) available for brusatol and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cytarabine; Drug Synergism; Female; Glucose; Glucosephosphate Dehydrogenase; Glutamate-Cysteine Ligase; Glycolysis; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Liver; Mice, Inbred BALB C; Mice, Nude; NF-E2-Related Factor 2; Quassins; THP-1 Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |